Sedation for Pediatric Echocardiography in Congenital Heart Disease: Dexmedetomidine versus Chloral Hydrate
Scientific Journal · 02.09.2026 · 5 (5) · 445-462
DOI: 10.56260/sciena.v5i5.390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Journal, online erschienen am 02.09.2026. Verfasst von Jane Elvina Sentosa und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Chloral hydrate is commonly used for paediatric transthoracic echocardiography (TTE) sedation, but safety concerns have prompted interest in alternatives. This meta-analysis compared intranasal dexmedetomidine with oral chloral hydrate for TTE sedation in children with known or suspected congenital heart disease (CHD).
Method
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement and was registered in PROSPERO [CRD420261376912]. PubMed/MEDLINE, Europe PMC, Cochrane CENTRAL, and ClinicalTrials.gov were searched to 30 September 2026. Risk of bias was assessed with Cochrane tools and certainty of evidence with the Grading of Recommendations Assessment, Development and Evaluation approach. Data were pooled using random-effects models, with Hartung–Knapp adjustment when ≥3 studies contributed.
Results
Four studies (one randomised trial and three cohort studies; 1414 children, 1187 in the primary analysis) were included. Single-dose sedation success did not differ in the randomised trial (risk ratio [RR] 1.02; 95% confidence interval [CI] 0.96–1.09), in the pooled non-randomised studies (RR 1.11; 95% CI 0.71–1.73), or overall (RR 1.08; 95% CI 0.85–1.36; very low certainty). Onset time and hypoxia did not differ significantly (very low certainty); rescue dose requirement was not pooled because its definition was not comparable across studies. Recovery time was shorter with dexmedetomidine (mean difference −9.96 min; 95% CI −18.71 to −1.22; low certainty). Bradycardia was more frequent with dexmedetomidine (RR 2.32; 95% CI 1.09–4.95; very low certainty), although no study reported its treatment.
Conclusion
In children with known or suspected CHD, the two agents showed no clear difference in TTE sedation success, whereas bradycardia was more frequent with dexmedetomidine. Given low-to-very-low certainty of evidence, neither agent can be considered superior; adequately powered randomised trials are needed.
Zitieren
APA
Sentosa, J. E., Alatas, A., Perdana, A., Ferdiana, K. A., Heriwardito, A., Hidayat, J., Soenarto, R. F., Omega, A., & Pranaya, A. Q. (2026). Sedation for Pediatric Echocardiography in Congenital Heart Disease: Dexmedetomidine versus Chloral Hydrate. Scientific Journal, 5(5), 445-462. https://doi.org/10.56260/sciena.v5i5.390
Vancouver
Sentosa JE, Alatas A, Perdana A, Ferdiana KA, Heriwardito A, Hidayat J, et al. Sedation for Pediatric Echocardiography in Congenital Heart Disease: Dexmedetomidine versus Chloral Hydrate. Scientific Journal. 2026;5(5):445-462. doi:10.56260/sciena.v5i5.390
BibTeX
@article{Sentosa2026,
author = {Sentosa, Jane Elvina and Alatas, Anas and Perdana, Aries and Ferdiana, Komang Ayu and Heriwardito, Aldy and Hidayat, Jefferson and Soenarto, Ratna Farida and Omega, Andy and Pranaya, Azhraa Qinan},
title = {Sedation for Pediatric Echocardiography in Congenital Heart Disease: Dexmedetomidine versus Chloral Hydrate},
journal = {Scientific Journal},
year = {2026},
volume = {5},
number = {5},
pages = {445--462},
doi = {10.56260/sciena.v5i5.390}
}
EUVIMED